Daewoong Pharmaceutical Announces Successful 'Extra Strength' Results of US Phase 2 Clinical Trial for High-dose Administration of Botulinum Toxin
High-dose Jeuveau, with a dosage double that of the existing 20 units, has succeeded in Phase 2 clinical trials as Extra StrengthDemonstrating a proven long-term efficacy of 6 months or 26 weeks, Jeuveau enhances global product competitiveness by
United States Clinical Trial For Administration Of Botulinum Toxin American Society For Dermatologic Surgery High Dose Jeuveau Line Scale Post Procedure Improvement Assessment Scale
Source: newswit.com